These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9510560)

  • 21. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor.
    Sant'Angelo DB; Robinson E; Janeway CA; Denzin LK
    Eur J Immunol; 2002 Sep; 32(9):2510-20. PubMed ID: 12207335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigen-based therapies using ignored determinants of beta cell antigens can more effectively inhibit late-stage autoimmune disease in diabetes-prone mice.
    Olcott AP; Tian J; Walker V; Dang H; Middleton B; Adorini L; Washburn L; Kaufman DL
    J Immunol; 2005 Aug; 175(3):1991-9. PubMed ID: 16034144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptide binding to major histocompatibility complex molecules.
    Barber LD; Parham P
    Annu Rev Cell Biol; 1993; 9():163-206. PubMed ID: 7506551
    [No Abstract]   [Full Text] [Related]  

  • 24. Predicting peptides bound to I-Ag7 class II histocompatibility molecules using a novel expectation-maximization alignment algorithm.
    Chang KY; Suri A; Unanue ER
    Proteomics; 2007 Feb; 7(3):367-77. PubMed ID: 17211830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
    Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
    Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired processing and presentation by MHC class II proteins in human diabetic cells.
    Yan G; Shi L; Penfornis A; Faustman DL
    J Immunol; 2003 Jan; 170(1):620-7. PubMed ID: 12496451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional consequences of the binding of MHC class II-derived peptides to MHC class II.
    Feili-Hariri M; Kao H; Mietzner TA; Morel PA
    Int Immunol; 1996 Dec; 8(12):1857-65. PubMed ID: 8982770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders.
    Carrasco-Marin E; Shimizu J; Kanagawa O; Unanue ER
    J Immunol; 1996 Jan; 156(2):450-8. PubMed ID: 8543793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of class II molecules in development of insulin-dependent diabetes mellitus in mice, rats and humans.
    Acha-Orbea H; McDevitt HO
    Curr Top Microbiol Immunol; 1990; 156():103-19. PubMed ID: 2199162
    [No Abstract]   [Full Text] [Related]  

  • 30. The accessibility of peptides bound to the mouse MHC class II molecule IEd studied by fluorescence.
    de Kroon AI
    FEBS Lett; 1994 Apr; 342(3):230-4. PubMed ID: 8150076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of HLA-DQ binding properties by differences in class II dimer stability and pH-dependent peptide interactions.
    Buckner J; Kwok WW; Nepom B; Nepom GT
    J Immunol; 1996 Dec; 157(11):4940-5. PubMed ID: 8943399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current studies on the identification of susceptibility genes for IDDM in NOD mice].
    Miyazaki J; Ishii M; Tashiro F
    Nihon Rinsho; 1994 Oct; 52(10):2772-7. PubMed ID: 7983813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoantibodies and CD4 T cells target a beta cell retroviral envelope protein in non-obese diabetic mice.
    Levisetti MG; Suri A; Vidavsky I; Gross ML; Kanagawa O; Unanue ER
    Int Immunol; 2003 Dec; 15(12):1473-83. PubMed ID: 14645156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes.
    Corper AL; Stratmann T; Apostolopoulos V; Scott CA; Garcia KC; Kang AS; Wilson IA; Teyton L
    Science; 2000 Apr; 288(5465):505-11. PubMed ID: 10775108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The inability of the nonobese diabetic class II molecule to form stable peptide complexes does not reflect a failure to interact productively with DM.
    Peterson M; Sant AJ
    J Immunol; 1998 Sep; 161(6):2961-7. PubMed ID: 9743359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of I-Ag7 beta chain in peptide binding and antigen recognition by T cells.
    Kanagawa O; Shimizu J; Unanue ER
    Int Immunol; 1997 Oct; 9(10):1523-6. PubMed ID: 9352357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of MHC class II molecules in the pathogenesis and prevention of Type I diabetes.
    McDevitt H
    Adv Exp Med Biol; 2001; 490():59-66. PubMed ID: 11505975
    [No Abstract]   [Full Text] [Related]  

  • 38. In APCs, the autologous peptides selected by the diabetogenic I-Ag7 molecule are unique and determined by the amino acid changes in the P9 pocket.
    Suri A; Vidavsky I; van der Drift K; Kanagawa O; Gross ML; Unanue ER
    J Immunol; 2002 Feb; 168(3):1235-43. PubMed ID: 11801660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assembly and intracellular transport of MHC class I and class II molecules.
    Jackson MR; Früh K; Karlsson L; Teyton L; Yang Y; Peterson PA
    Cold Spring Harb Symp Quant Biol; 1995; 60():249-61. PubMed ID: 8824398
    [No Abstract]   [Full Text] [Related]  

  • 40. Binding of single substituted promiscuous and designer peptides to purified DRB1*0101.
    Macklin KD; Conti-Fine BM
    Biochem Biophys Res Commun; 1998 Jan; 242(2):322-6. PubMed ID: 9446793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.